LENZ Therapeutics, Inc. - 10-Q Filing
LENZ Therapeutics filed its quarterly report on Form 10-Q for the period ended March 31, 2026. The filing provides financial and operational updates including revenue from product sales and license agreements, expenses such as cost of goods sold ($X), selling, general, and administrative expenses ($Y), research and development costs ($Z). It also outlines key milestones under its CORXEL licensing agreement and details related-party transactions.
Tickers: $LENZ